Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Monday. The brokerage presently has a $1.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective suggests a potential upside of 2.73% from the stock’s current price.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

Several other research firms have also recently weighed in on APTO. HC Wainwright initiated coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They set a “hold” rating on the stock. ValuEngine upgraded shares of Aptose Biosciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 12th. Canaccord Genuity restated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Friday, May 12th. Finally, Rodman & Renshaw initiated coverage on shares of Aptose Biosciences in a report on Thursday, June 8th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Aptose Biosciences has an average rating of “Hold” and an average price target of $7.13.

Aptose Biosciences (APTO) traded up 0.6966% during trading on Monday, hitting $1.4601. 171,255 shares of the stock were exchanged. The firm’s 50-day moving average is $1.43 and its 200 day moving average is $1.17. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $3.20. The firm’s market cap is $31.76 million.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.07. Analysts expect that Aptose Biosciences will post ($1.04) earnings per share for the current fiscal year.

WARNING: “Aptose Biosciences, Inc. (NASDAQ:APTO) Upgraded to Buy by Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/aptose-biosciences-inc-nasdaqapto-upgraded-to-buy-by-zacks-investment-research/1487926.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.